Phase I clinical trials (NCT00666926) of VS-6062 have been completed as the first specific FAK inhibitor in clinical trials (head and neck cancer, prostate cancer and pancreatic cancer). This evidence concerns the gene PTK2 and pancreatic neoplasm.